Gold Prices Hit One-Week High as Oil Falls, Fed Rate Outlook Weighed 
Anthropic Launches Claude Dashboards and Motion AI Tools 
Deutsche Bank CEO Urges Faster German Economic Reforms 
XRP Ledger Activates New Security Feature for Banks and Stablecoins 
Gold Prices Fall as Fed Signals Another Rate Hike 
Blockchain.com Seeks CFTC Approval for Prediction Markets and Crypto Derivatives 
DWF Labs Sues BitGo for $114 Million Over Alleged Token Sales Breach 
Moscow Exchange to Launch Crypto Trading on December 1 
Stellar Overtakes Ethereum in RWA Fund Inflows as XRP Leads Commodities 
Gold Prices Rise as Hormuz Tensions Fuel Inflation Risks 
Gold Prices Rise as Dollar Weakens, Treasury Yields Fall 
Disney Expands Infinity Vision to Challenge Imax 
Apple Names Steve Smith M&A Chief in Leadership Shakeup 
Iran Refuses to Halt Uranium Enrichment Amid US Nuclear Demands 
US Suspends Microsoft, Adobe From Green Card Program 
Trump Secures Russian Diesel Deal as US Fuel Prices Surge 
OpenAI Annualized Revenue Hits $50 Billion, Below Earlier Estimates 
Add as a preferred source on Google
Eli Lilly gets a subpoena from the U.S. Department of Justice with regards to its manufacturing factory in New Jersey that produces COVID-19 treatment called bamlanivimab. Based on the report, the DOJ wants the pharmaceutical company to forward some documents.
As per Reuters, while it was not specified what documents are being requested by the officials, they are something related to Eli Lilly’s factory site in Branchburg, New Jersey. The company said that it is actively participating and fully cooperating with the investigation.
The issue with Eli Lilly’s NJ plant
Earlier this month, some of Eli Lilly’s employees alleged that an executive in the NJ plant altered the documents so it can pass quality control without a problem. The papers are required by regulators for the operation of the company’s factory, but with the modification, the employees feared it would cause serious quality control issues.
It was relayed that in November 2019, inspectors from the U.S. Food and Drug Administration were sent over to check Eli Lilly’s Branchburg factory. They discovered that much of the data related to manufacturing processes were deleted while others were not inappropriately audited.
The pharmaceutical company is also said to be facing issues with its quality control and production at its plant in Indianapolis. This is the site where bamlanivimab and other medicines are being bottled.
Lilly conducting its own internal probe
As per Financial Post, Eli Lilly also launched its own investigation concerning the allegations. The company also hired counsel who will carry out an independent probe in its New Jersey facility.
“Lilly is deeply committed to manufacturing high-quality medicines for patients who need them, and the safety and quality of our products is our highest priority,” the firm stated.
In any case, while the investigation is ongoing, Eli Lilly published the subpoena issued to them by the DOJ. This move shows that the company is being transparent with the investigation and doing its best to resolve the problems too. Meanwhile, the company could not comment further on the case as of this time since a conclusion has not been reached yet.
